- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Partial volume correction for Lu-177-PSMA SPECT ; volume:11 ; number:1 ; day:12 ; month:11 ; year:2024 ; pages:1-15 ; date:12.2024
EJNMMI Physics ; 11, Heft 1 (12.11.2024), 1-15, 12.2024
- Klassifikation
-
Recht
- Urheber
-
Liu, Yibin
Lu, Zhonglin
Chen, Gefei
Shi, Kuangyu
Mok, Greta S. P.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40658-024-00697-1
- URN
-
urn:nbn:de:101:1-2501292105300.536235267036
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Liu, Yibin
- Lu, Zhonglin
- Chen, Gefei
- Shi, Kuangyu
- Mok, Greta S. P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
![Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer](/assets/placeholder/searchResultMediaUnknown.png)
Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT
Anatomy-based correction of kidney PVE on $$^177}\text{Lu}$$ 177 Lu SPECT images
An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
Comparison of a 3D CZT and conventional SPECT/CT system for quantitative Lu-177 SPECT imaging
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
Klinische Beurteilung der Wirksamkeit und Toxizität der Lu-177-PSMA-Ligandentherapie bei kastrationsresistentem Prostatakarzinom
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
Retrospektive Analyse von Lu-177-PSMA-617-Therapien bei Patienten mit metastasiertem Prostatakarzinom am Universitätsklinikum Regensburg
Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT
Anatomy-based correction of kidney PVE on $$^177}\text{Lu}$$ 177 Lu SPECT images
An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
Comparison of a 3D CZT and conventional SPECT/CT system for quantitative Lu-177 SPECT imaging
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
Klinische Beurteilung der Wirksamkeit und Toxizität der Lu-177-PSMA-Ligandentherapie bei kastrationsresistentem Prostatakarzinom
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
Retrospektive Analyse von Lu-177-PSMA-617-Therapien bei Patienten mit metastasiertem Prostatakarzinom am Universitätsklinikum Regensburg
Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT
Anatomy-based correction of kidney PVE on $$^177}\text{Lu}$$ 177 Lu SPECT images
An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
Comparison of a 3D CZT and conventional SPECT/CT system for quantitative Lu-177 SPECT imaging
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
Klinische Beurteilung der Wirksamkeit und Toxizität der Lu-177-PSMA-Ligandentherapie bei kastrationsresistentem Prostatakarzinom
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Urinary excretion kinetics of [177Lu]Lu-PSMA-617